CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc., a clinical stage drug development company built on a proprietary pathway pharmacology platform, today announced that Jill C. Milne, Ph.D., chief executive officer and co-founder of Catabasis, will present an overview of Catabasis and its lead drug development programs at the Wedbush 2014 Life Sciences Management Access Conference. The conference is being held August 12-13, 2014, at Le Parker Meridien Hotel in New York. Dr. Milne’s presentation will take place at 1:55 p.m. ET on Wednesday, August 13.
Catabasis Pharmaceuticals is leveraging its pathway pharmacology drug development platform to bring important medicines to patients with severe lipid disorders and rare inflammatory diseases. The Company’s mission is to address difficult-to-treat diseases through the simultaneous modulation of multiple targets in a disease pathway. For more information on our technology and pipeline of drug candidates, please visit www.catabasis.com.